SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Joe E. who wrote (3328)12/16/1997 1:05:00 AM
From: JOHN W.  Read Replies (2) | Respond to of 6136
 
I agree. However, this 6-7% move for both VRTX and AGPH so late in the trading day, is odd. Does anyone have an possible explanation?

We all know I suffer from paranoia. The trading action prior to the Roche announcement still gnaws at my gut, especially by the company insiders. The individual investor seems to be always at a disadvantage.



To: Joe E. who wrote (3328)12/16/1997 1:18:00 AM
From: Steve Fancy  Respond to of 6136
 
Hi Joe, I second the motion...poor on the good news, let's take it to 55...or 45...or even 40 sounds great! I'll keep quiet.

sf



To: Joe E. who wrote (3328)12/16/1997 1:27:00 AM
From: JOHN W.  Respond to of 6136
 
Thestreet.com is at it again, plugging LGND and taking a pot shot (unexplained) at AGPH and AMGN (not bad company for AGPH-Jesse).

The reference was that the street likes to know their is a pipeline, but only cares when a company needs one badly and then notes AGPH and AMGN as examples. then later, notes the rising resistance problem for the cocktail.

C'mon Cramer, it is way too obvious now, treading on thin ice.

And people wonder why I am paranoid.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News